Trade Standard BioTools Inc - LAB CFD

Trading Conditions

• Spread: 0.0226
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 2.4137
• Open: 2.2637
• 1-Year Change: 31.86%
• Day's Range: 2.1937 - 2.3837

Standard BioTools Inc Company profile

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.

Equity composition

Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.